UnivTrevesV1, Main, Exploration, bibRecord, 001B61

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

Identifieur interne : 001B61 ( Main/Exploration ); précédent : 001B60; suivant : 001B62

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

Auteurs : C-H Köhne [Allemagne] ; R. Catane [Israël] ; B. Klein [Israël] ; M. Ducreux [France] ; P. Thuss-Patience [Allemagne] ; N. Niederle [Allemagne] ; M. Gips [Israël] ; P. Preusser [Allemagne] ; A. Knuth [Allemagne] ; M. Clemens [Allemagne] ; R. Bugat [France] ; I. Fige [Israël] ; A. Shani [Israël] ; B. Fages [France] ; D. Di Betta [France] ; C. Jacques [France] ; H. J. Wilke [Allemagne]

Source :

British journal of cancer [ 0007-0920 ] ; 2003.

RBID : Pascal:04-0030089

Descripteurs français

Pascal (Inist)
- Adénocarcinome, Estomac, Stade avancé, Irinotécan, Inhibiteur enzyme, DNA topoisomerase (ATP-hydrolysing), Anticancéreux, Essai clinique phase II, Etude multicentrique, Efficacité traitement, Toxicité, Complication, Pronostic, Chimiothérapie, Traitement, Voie intraveineuse, Homme, Pyrano indolizino quinoléine dérivé.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adenocarcinoma, Advanced stage, Antineoplastic agent, Chemotherapy, Complication, DNA topoisomerase (ATP-hydrolysing), Enzyme inhibitor, Human, Intravenous administration, Irinotecan, Multicenter study, Phase II trial, Prognosis, Stomach, Toxicity, Treatment, Treatment efficiency.

Abstract

To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastnc cancer received irinotecan 350 mg m^-2 every 3 weeks administered as a 30 min infusion. Among the 35 patients evaluable for response, two complete and five partial responses were recorded (response rate: 20.0% (95% Cl:8.4 - 36.9%)). In total, 16 patients achieved stable disease and 12 progressive disease. In all, 66 percent of the patients benefited from tumour growth control. The median time to progression was 3.0 months (95% Cl: 2.3-4.4%). The median overall survival was 7.1 months (95% Cl: 5.2-9.0%). The probability of being alive at 6 months and 9 months was 61.0 and 32.4%, respectively. The median number of cycles per patient was 3 (range I -14), and the relative dose intensity was 0.98. The most common grade 3-4 toxicities by patients were diarrhoea 20%, asthenia 10%, nausea 7.5%, vomiting 5.0%, abdominal pain 5%, neutropenia 38.5%, leucopenia 28.2%, anaemia 12.8% and thrombocytopenia 5.1%. Febrile neutropenia occurred in 12.5% of patients. These findings indicate that innotecan is active and well tolerated in patients with metastatic gastric adenocarcinoma and warrants further evaluation in this clinical setting.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376958

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial</title>
<author><name sortKey="Kohne, C H" sort="Kohne, C H" uniqKey="Kohne C" first="C-H" last="Köhne">C-H Köhne</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Robert Rossle Klinik Chanté University Hospital</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Catane, R" sort="Catane, R" uniqKey="Catane R" first="R." last="Catane">R. Catane</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Shaare Zedek Medical centre</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Shaare Zedek Medical centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klein, B" sort="Klein, B" uniqKey="Klein B" first="B." last="Klein">B. Klein</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Robin Medical Centre, Oncology, Golda Campus</s1>
<s2>Petach-Tikva</s2>
<s3>ISR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Petach-Tikva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ducreux, M" sort="Ducreux, M" uniqKey="Ducreux M" first="M." last="Ducreux">M. Ducreux</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Insntut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Insntut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Insntut Gustave Roussy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thuss Patience, P" sort="Thuss Patience, P" uniqKey="Thuss Patience P" first="P." last="Thuss-Patience">P. Thuss-Patience</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Robert Rossle Klinik Chanté University Hospital</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niederle, N" sort="Niederle, N" uniqKey="Niederle N" first="N." last="Niederle">N. Niederle</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Klinikum Leverkusen</s1>
<s2>Leverkusen</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Leverkusen</wicri:noRegion>
<wicri:noRegion>Klinikum Leverkusen</wicri:noRegion>
<wicri:noRegion>Klinikum Leverkusen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gips, M" sort="Gips, M" uniqKey="Gips M" first="M." last="Gips">M. Gips</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hadassah Ein Karem Medical Centre</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Hadassah Ein Karem Medical Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Preusser, P" sort="Preusser, P" uniqKey="Preusser P" first="P." last="Preusser">P. Preusser</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Chirurgische Onkologie, Department of General Surgery, Muenster University Hospital</s1>
<s2>Germany</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Germany</wicri:noRegion>
<wicri:noRegion>Muenster University Hospital</wicri:noRegion>
<wicri:noRegion>Germany</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Knuth, A" sort="Knuth, A" uniqKey="Knuth A" first="A." last="Knuth">A. Knuth</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>II Medizinische Klinik Krankenhaus Nordwest</s1>
<s2>Frankfurt</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clemens, M" sort="Clemens, M" uniqKey="Clemens M" first="M." last="Clemens">M. Clemens</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Krankenanstalt Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Trier</wicri:noRegion>
<wicri:noRegion>Krankenanstalt Mutterhaus der Borromaerinnen</wicri:noRegion>
<wicri:noRegion>Krankenanstalt Mutterhaus der Borromaerinnen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
<affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Institut Claudius Regaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fige, I" sort="Fige, I" uniqKey="Fige I" first="I." last="Fige">I. Fige</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Beilinson Medical cenfer</s1>
<s2>Petach-Tivka</s2>
<s3>ISR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Beilinson Medical cenfer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shani, A" sort="Shani, A" uniqKey="Shani A" first="A." last="Shani">A. Shani</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Kaplan Medical Center</s1>
<s2>Rehouot Netanya</s2>
<s3>ISR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Kaplan Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fages, B" sort="Fages, B" uniqKey="Fages B" first="B." last="Fages">B. Fages</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Aventis</s1>
<s2>Antony</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Antony</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Betta, D" sort="Di Betta, D" uniqKey="Di Betta D" first="D." last="Di Betta">D. Di Betta</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Aventis</s1>
<s2>Antony</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Antony</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacques, C" sort="Jacques, C" uniqKey="Jacques C" first="C." last="Jacques">C. Jacques</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Aventis</s1>
<s2>Antony</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Antony</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wilke, H J" sort="Wilke, H J" uniqKey="Wilke H" first="H. J." last="Wilke">H. J. Wilke</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Kliniken Essen Mitre</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Essen</wicri:noRegion>
<wicri:noRegion>Kliniken Essen Mitre</wicri:noRegion>
<wicri:noRegion>Kliniken Essen Mitre</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0030089</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0030089 INIST</idno>
<idno type="RBID">Pascal:04-0030089</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B99</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000304</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000996</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000996</idno>
<idno type="wicri:doubleKey">0007-0920:2003:Kohne C:irinotecan:is:active</idno>
<idno type="wicri:Area/Main/Merge">001D89</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376958</idno>
<idno type="RBID">PMC:2376958</idno>
<idno type="wicri:Area/Pmc/Corpus">000010</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000010</idno>
<idno type="wicri:Area/Pmc/Curation">000010</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000010</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000186</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000186</idno>
<idno type="wicri:Area/Ncbi/Merge">000123</idno>
<idno type="wicri:Area/Ncbi/Curation">000123</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000123</idno>
<idno type="wicri:doubleKey">0007-0920:2003:Kohne C:irinotecan:is:active</idno>
<idno type="wicri:Area/Main/Merge">001C46</idno>
<idno type="wicri:Area/Main/Curation">001B61</idno>
<idno type="wicri:Area/Main/Exploration">001B61</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial</title>
<author><name sortKey="Kohne, C H" sort="Kohne, C H" uniqKey="Kohne C" first="C-H" last="Köhne">C-H Köhne</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Robert Rossle Klinik Chanté University Hospital</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Catane, R" sort="Catane, R" uniqKey="Catane R" first="R." last="Catane">R. Catane</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Shaare Zedek Medical centre</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Shaare Zedek Medical centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klein, B" sort="Klein, B" uniqKey="Klein B" first="B." last="Klein">B. Klein</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Robin Medical Centre, Oncology, Golda Campus</s1>
<s2>Petach-Tikva</s2>
<s3>ISR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Petach-Tikva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ducreux, M" sort="Ducreux, M" uniqKey="Ducreux M" first="M." last="Ducreux">M. Ducreux</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Insntut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Insntut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Insntut Gustave Roussy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thuss Patience, P" sort="Thuss Patience, P" uniqKey="Thuss Patience P" first="P." last="Thuss-Patience">P. Thuss-Patience</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Robert Rossle Klinik Chanté University Hospital</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niederle, N" sort="Niederle, N" uniqKey="Niederle N" first="N." last="Niederle">N. Niederle</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Klinikum Leverkusen</s1>
<s2>Leverkusen</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Leverkusen</wicri:noRegion>
<wicri:noRegion>Klinikum Leverkusen</wicri:noRegion>
<wicri:noRegion>Klinikum Leverkusen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gips, M" sort="Gips, M" uniqKey="Gips M" first="M." last="Gips">M. Gips</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hadassah Ein Karem Medical Centre</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Hadassah Ein Karem Medical Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Preusser, P" sort="Preusser, P" uniqKey="Preusser P" first="P." last="Preusser">P. Preusser</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Chirurgische Onkologie, Department of General Surgery, Muenster University Hospital</s1>
<s2>Germany</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Germany</wicri:noRegion>
<wicri:noRegion>Muenster University Hospital</wicri:noRegion>
<wicri:noRegion>Germany</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Knuth, A" sort="Knuth, A" uniqKey="Knuth A" first="A." last="Knuth">A. Knuth</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>II Medizinische Klinik Krankenhaus Nordwest</s1>
<s2>Frankfurt</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clemens, M" sort="Clemens, M" uniqKey="Clemens M" first="M." last="Clemens">M. Clemens</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Krankenanstalt Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Trier</wicri:noRegion>
<wicri:noRegion>Krankenanstalt Mutterhaus der Borromaerinnen</wicri:noRegion>
<wicri:noRegion>Krankenanstalt Mutterhaus der Borromaerinnen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
<affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Institut Claudius Regaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fige, I" sort="Fige, I" uniqKey="Fige I" first="I." last="Fige">I. Fige</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Beilinson Medical cenfer</s1>
<s2>Petach-Tivka</s2>
<s3>ISR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Beilinson Medical cenfer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shani, A" sort="Shani, A" uniqKey="Shani A" first="A." last="Shani">A. Shani</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Kaplan Medical Center</s1>
<s2>Rehouot Netanya</s2>
<s3>ISR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Kaplan Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fages, B" sort="Fages, B" uniqKey="Fages B" first="B." last="Fages">B. Fages</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Aventis</s1>
<s2>Antony</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Antony</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Betta, D" sort="Di Betta, D" uniqKey="Di Betta D" first="D." last="Di Betta">D. Di Betta</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Aventis</s1>
<s2>Antony</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Antony</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacques, C" sort="Jacques, C" uniqKey="Jacques C" first="C." last="Jacques">C. Jacques</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Aventis</s1>
<s2>Antony</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Antony</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wilke, H J" sort="Wilke, H J" uniqKey="Wilke H" first="H. J." last="Wilke">H. J. Wilke</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Kliniken Essen Mitre</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Essen</wicri:noRegion>
<wicri:noRegion>Kliniken Essen Mitre</wicri:noRegion>
<wicri:noRegion>Kliniken Essen Mitre</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma</term>
<term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>DNA topoisomerase (ATP-hydrolysing)</term>
<term>Enzyme inhibitor</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Irinotecan</term>
<term>Multicenter study</term>
<term>Phase II trial</term>
<term>Prognosis</term>
<term>Stomach</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adénocarcinome</term>
<term>Estomac</term>
<term>Stade avancé</term>
<term>Irinotécan</term>
<term>Inhibiteur enzyme</term>
<term>DNA topoisomerase (ATP-hydrolysing)</term>
<term>Anticancéreux</term>
<term>Essai clinique phase II</term>
<term>Etude multicentrique</term>
<term>Efficacité traitement</term>
<term>Toxicité</term>
<term>Complication</term>
<term>Pronostic</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Voie intraveineuse</term>
<term>Homme</term>
<term>Pyrano indolizino quinoléine dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastnc cancer received irinotecan 350 mg m<sup>-2</sup>
 every 3 weeks administered as a 30 min infusion. Among the 35 patients evaluable for response, two complete and five partial responses were recorded (response rate: 20.0% (95% Cl:8.4 - 36.9%)). In total, 16 patients achieved stable disease and 12 progressive disease. In all, 66 percent of the patients benefited from tumour growth control. The median time to progression was 3.0 months (95% Cl: 2.3-4.4%). The median overall survival was 7.1 months (95% Cl: 5.2-9.0%). The probability of being alive at 6 months and 9 months was 61.0 and 32.4%, respectively. The median number of cycles per patient was 3 (range I -14), and the relative dose intensity was 0.98. The most common grade 3-4 toxicities by patients were diarrhoea 20%, asthenia 10%, nausea 7.5%, vomiting 5.0%, abdominal pain 5%, neutropenia 38.5%, leucopenia 28.2%, anaemia 12.8% and thrombocytopenia 5.1%. Febrile neutropenia occurred in 12.5% of patients. These findings indicate that innotecan is active and well tolerated in patients with metastatic gastric adenocarcinoma and warrants further evaluation in this clinical setting.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>France</li>
<li>Israël</li>
</country>
<region><li>Berlin</li>
<li>District de Darmstadt</li>
<li>Hesse (Land)</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Antony</li>
<li>Berlin</li>
<li>Francfort-sur-le-Main</li>
<li>Toulouse</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Berlin"><name sortKey="Kohne, C H" sort="Kohne, C H" uniqKey="Kohne C" first="C-H" last="Köhne">C-H Köhne</name>
</region>
<name sortKey="Clemens, M" sort="Clemens, M" uniqKey="Clemens M" first="M." last="Clemens">M. Clemens</name>
<name sortKey="Knuth, A" sort="Knuth, A" uniqKey="Knuth A" first="A." last="Knuth">A. Knuth</name>
<name sortKey="Niederle, N" sort="Niederle, N" uniqKey="Niederle N" first="N." last="Niederle">N. Niederle</name>
<name sortKey="Preusser, P" sort="Preusser, P" uniqKey="Preusser P" first="P." last="Preusser">P. Preusser</name>
<name sortKey="Thuss Patience, P" sort="Thuss Patience, P" uniqKey="Thuss Patience P" first="P." last="Thuss-Patience">P. Thuss-Patience</name>
<name sortKey="Wilke, H J" sort="Wilke, H J" uniqKey="Wilke H" first="H. J." last="Wilke">H. J. Wilke</name>
</country>
<country name="Israël"><noRegion><name sortKey="Catane, R" sort="Catane, R" uniqKey="Catane R" first="R." last="Catane">R. Catane</name>
</noRegion>
<name sortKey="Fige, I" sort="Fige, I" uniqKey="Fige I" first="I." last="Fige">I. Fige</name>
<name sortKey="Gips, M" sort="Gips, M" uniqKey="Gips M" first="M." last="Gips">M. Gips</name>
<name sortKey="Klein, B" sort="Klein, B" uniqKey="Klein B" first="B." last="Klein">B. Klein</name>
<name sortKey="Shani, A" sort="Shani, A" uniqKey="Shani A" first="A." last="Shani">A. Shani</name>
</country>
<country name="France"><noRegion><name sortKey="Ducreux, M" sort="Ducreux, M" uniqKey="Ducreux M" first="M." last="Ducreux">M. Ducreux</name>
</noRegion>
<name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
<name sortKey="Di Betta, D" sort="Di Betta, D" uniqKey="Di Betta D" first="D." last="Di Betta">D. Di Betta</name>
<name sortKey="Fages, B" sort="Fages, B" uniqKey="Fages B" first="B." last="Fages">B. Fages</name>
<name sortKey="Jacques, C" sort="Jacques, C" uniqKey="Jacques C" first="C." last="Jacques">C. Jacques</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B61 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B61 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Rhénanie
   |area=    UnivTrevesV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:04-0030089
   |texte=   Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Jul 22 16:29:01 2017. Site generation: Wed Feb 28 14:55:37 2024

Serveur d'exploration sur l'Université de Trèves

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur l'Université de Trèves
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.